The Boston area has long been home to innovation that leads to impactful new drugs. But manufacturing those drugs for clinical trials often involves international partners and supply chains. The vulnerabilities of that system have become all too apparent during the Covid-19 pandemic. Now Snapdragon Chemistry, co-founded by MIT Professor and Associate Provost Tim Jamison, is helping pharmaceutical companies manufacture drugs locally to shorten the time it takes for new drugs to get to patients. Snapdragon essentially starts as a chemistry lab, running experiments on behalf of pharmaceutical customers to create molecules of interest.

Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar energy, and polymer chemistry. The system, described in the August 8 issue of Science, could free up bench chemists from a variety of routine and time-consuming tasks, and may suggest possibilities for how to make new molecular compounds, according to the study co-leaders Klavs F. Jensen, the Warren K. Lewis Professor of Chemical Engineering, and Timothy F. Jamison, the Robert R. Taylor Professor of Chemistry and associate provost at MIT. The technology "has the promise to help people cut out all the tedious parts of molecule building," including looking up potential reaction pathways and building the components of a molecular assembly line each time a new molecule is produced, says Jensen. "And as a chemist, it may give you inspirations for new reactions that you hadn't thought about before," he adds. The new system combines three main steps.

Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar energy, and polymer chemistry. The system, described in the August 8 issue of Science, could free up bench chemists from a variety of routine and time-consuming tasks, and may suggest possibilities for how to make new molecular compounds, according to the study co-leaders Klavs F. Jensen, the Warren K. Lewis Professor of Chemical Engineering, and Timothy F. Jamison, the Robert R. Taylor Professor of Chemistry and associate provost at MIT. The technology "has the promise to help people cut out all the tedious parts of molecule building," including looking up potential reaction pathways and building the components of a molecular assembly line each time a new molecule is produced, says Jensen. "And as a chemist, it may give you inspirations for new reactions that you hadn't thought about before," he adds. The new system combines three main steps.

Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar energy, and polymer chemistry. The system, described in the August 8 issue of Science, could free up bench chemists from a variety of routine and time-consuming tasks, and may suggest possibilities for how to make new molecular compounds, according to the study co-leaders Klavs F. Jensen, the Warren K. Lewis Professor of Chemical Engineering, and Timothy F. Jamison, the Robert R. Taylor Professor of Chemistry and associate provost at MIT. The technology "has the promise to help people cut out all the tedious parts of molecule building," including looking up potential reaction pathways and building the components of a molecular assembly line each time a new molecule is produced, says Jensen. "And as a chemist, it may give you inspirations for new reactions that you hadn't thought about before," he adds. The new system combines three main steps.

Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar energy, and polymer chemistry. The system, described in the August 8 issue of Science, could free up bench chemists from a variety of routine and time-consuming tasks, and may suggest possibilities for how to make new molecular compounds, according to the study co-leaders Klavs F. Jensen, the Warren K. Lewis Professor of Chemical Engineering, and Timothy F. Jamison, the Robert R. Taylor Professor of Chemistry and associate provost at MIT. The technology "has the promise to help people cut out all the tedious parts of molecule building," including looking up potential reaction pathways and building the components of a molecular assembly line each time a new molecule is produced, says Jensen. "And as a chemist, it may give you inspirations for new reactions that you hadn't thought about before," he adds. The new system combines three main steps.

Frost & Sullivan describes robotic process automation (RPA) as software that incorporates technologies such as artificial intelligence (AI) and machine learning (ML) to automate routine, high-volume tasks that are sensitive to human error. While RPA can boost business efficiencies and ROI without increasing costs, it should not be seen as a replacement for existing business process management (BPM) systems. Jamison who was commenting on the company's recently published whitepaper Robotic Process Automation: A New Era of Agent Engagement, which examined the increasingly important role RPA is playing in contact centres. Across all industries, RPA acts as hidden glue that ties together many business processes, with RPA workforces improving organisational efficiency by offloading live resources, improving accuracy, maintaining compliance, and reducing costs. The whitepaper notes that the focus of the contact centre has shifted from its early days as a customer service cost centre to a customer engagement hub that utilises advanced analytic applications to provide insights into agent performance and workforce management.

It's been a big year in healthcare technology. Healthcare Analytics News reached out to experts across our 8 coverage areas to determine which companies, people, and projects made the biggest waves. The winners of 2017 ushered in advances that have turned heads, resulted in measurable improvements, and given reason to believe that this high-speed sector is not built on hype alone. Big Data: Montefiore Medical Center Numbers can save lives. The traditional relational database in place at Montefiore Medical Center, Albert Einstein College of Medicine, in Bronx, New York, has been dredged out and filled in with the center's innovative semantic data lake project, to plumb the depths of predictive analytics.

Upfront, he let the reporters and editors in the room know he thought their reporting has been unfair to him. During the wide-ranging conversation, Trump denounced Nazi celebrations in Washington, D.C., offered Jared Kushner as a peace-broker between Israel and Palestine, promised to stay open-minded about the Paris climate-change accord, and mused that prosecuting the Clintons would be a nationally divisive move. He also stood by his appointment of Steve Bannon, saying that had he thought Bannon were racist he wouldn't have hired him. The new feature is an expansion of its "popular times" product. There are currently 32.9 million millionaires.